We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial.
- Authors
Bergmark, Brian A.; Cannon, Christopher P.; White, William B.; Jarolim, Petr; Liu, Yuyin; Bonaca, Marc P.; Zannad, Faiez; Morrow, David A.
- Abstract
Aim To investigate adiponectin levels and cardiovascular ( CV) outcomes in patients with diabetes and recent acute coronary syndrome ( ACS). Materials and methods We analysed baseline adiponectin concentration and CV outcomes in 5213 patients with type 2 diabetes enrolled in the EXAMINE trial of alogliptin vs placebo 15 to 90 days (median 45 days) after ACS. Event rates at 18 months are reported. Results The median (interquartile range) baseline adiponectin concentration was 5.2 (3.5-7.9) μg/ mL. Patients with the highest baseline adiponectin concentration (quartile [ Q]4) were at significantly higher risk of death from a CV event (8.4% vs 1.7%; P < .0001), hospitalization for heart failure ( HF; 7.5% vs 1.7%; P < .0001), and all-cause mortality (10.8% vs 2.4%; P < .0001) compared with those in Q1. After adjusting for age, sex, index event, HF, estimated glomerular filtration rate and hypertension, adiponectin concentration in Q4 remained associated with an increased risk of death from CV causes (hazard ratio [ HR] 2.43, 95% confidence interval [ CI] 1.52, 3.88), all-cause mortality ( HR 2.45, 95% CI 1.65, 3.64), and HF ( HR 2.44, 95% CI 1.47, 4.05), without change after stratification by body mass index. There was no significant difference in the rate of myocardial infarction or stroke. Conclusions In this contemporary population of patients with diabetes and ACS, adiponectin concentration was independently associated with increased risk of death from CV causes, all-cause mortality, and hospitalization for HF. The relationship between adiponectin and CV outcomes is complex and deserves further study.
- Subjects
ADIPONECTIN; ACUTE coronary syndrome; CARDIOVASCULAR disease related mortality; PEOPLE with diabetes; HEALTH outcome assessment; PATIENTS
- Publication
Diabetes, Obesity & Metabolism, 2017, Vol 19, Issue 7, p962
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.12905